Last updated: September 8, 2026
The commercial product combining bupropion hydrochloride and naltrexone hydrochloride is Contrave, an extended-release oral medicine approved by the FDA in 2014 for chronic weight management. Its market position depends on three factors: the sharp growth of obesity treatment, intense competition from GLP-1 and GIP/GLP-1 therapies, and the erosion of branded exclusivity as generic manufacturers challenge the extended-release formulation.
The active ingredients are individually generic and inexpensive. Commercial value is concentrated in the fixed-dose extended-release product, the titration schedule, clinical data, brand distribution, payer access, and formulation-related intellectual property.
What is the market status of bupropion hydrochloride and naltrexone hydrochloride?
Bupropion hydrochloride is an antidepressant and smoking-cessation medicine. Naltrexone hydrochloride is an opioid antagonist used in alcohol-use and opioid-use disorder treatment. The combination is marketed as Contrave for obesity management.
| Attribute |
Contrave |
| Active ingredients |
Naltrexone hydrochloride and bupropion hydrochloride |
| Dosage form |
Extended-release tablets |
| Strength per tablet |
8 mg naltrexone / 90 mg bupropion |
| Maximum daily dose |
Two tablets twice daily |
| FDA approval |
September 2014 |
| Sponsor at approval |
Orexigen Therapeutics |
| Current commercial owner |
Currax Pharmaceuticals |
| Indication |
Chronic weight management in adults with obesity or overweight plus a weight-related condition |
| Administration |
Oral, with a four-week dose escalation |
| Therapeutic category |
Anti-obesity pharmacotherapy |
The product is indicated with a reduced-calorie diet and increased physical activity. The FDA label requires discontinuation if a patient has not achieved at least 5% weight loss after 12 weeks on the maintenance dose. Contraindications include uncontrolled hypertension, seizure disorder, anorexia or bulimia nervosa, chronic opioid use, acute opioid withdrawal, and use of monoamine oxidase inhibitors. [1]
The ingredients have no meaningful standalone patent value for obesity treatment. The commercial asset is the combination product and its extended-release delivery system.
How large is the market for Contrave and other oral obesity drugs?
The addressable obesity market has expanded rapidly because of rising diagnosis rates, greater employer and payer attention, and increased acceptance of chronic pharmacologic treatment. Contrave benefits from this expansion but competes against medicines with substantially higher average weight-loss results.
| Product |
Active ingredients |
Route |
Approximate clinical positioning |
| Contrave |
Naltrexone/bupropion ER |
Oral |
Moderate weight loss; non-GLP-1 option |
| Qsymia |
Phentermine/topiramate ER |
Oral |
Higher average weight loss than Contrave; controlled-substance considerations |
| Wegovy |
Semaglutide |
Injectable |
High efficacy; major supply, access and cost considerations |
| Zepbound |
Tirzepatide |
Injectable |
Very high efficacy; rapidly expanding obesity market share |
| Saxenda |
Liraglutide |
Injectable |
Established GLP-1 option; facing competitive and pricing pressure |
| Xenical/Alli |
Orlistat |
Oral |
Lower-cost option with gastrointestinal tolerability limitations |
In clinical trials, Contrave produced average weight loss meaningfully above placebo but below the results reported for semaglutide and tirzepatide in large obesity studies. This efficacy gap limits premium pricing and makes payer coverage important. [1-4]
Contrave’s principal commercial advantages are oral administration, a lower price than branded injectable incretin therapies, and the absence of a GLP-1 supply-chain requirement. Its disadvantages are lower efficacy, neuropsychiatric and seizure-related warnings, opioid-related contraindications, a complex titration schedule, and poor suitability for patients requiring chronic opioid analgesia.
What is the financial trajectory of Contrave?
Contrave’s financial trajectory has passed through three distinct stages:
- Initial commercialization under Orexigen, with substantial spending on market development and cardiovascular-outcomes requirements.
- Ownership transfer following Orexigen’s financial distress and bankruptcy proceedings.
- A more focused commercial model under Currax, emphasizing telehealth, direct-to-consumer promotion, payer access, and lower-cost obesity treatment.
Orexigen filed for bankruptcy in 2018 after reporting significant financial pressure. Nalpropion Pharmaceuticals acquired the Contrave business and related assets, and Currax subsequently became the operating commercial platform. [5-7]
Public disclosures indicate that Contrave became a meaningful branded-product asset after the ownership transition. Currax has reported annual Contrave net sales above $100 million in public company materials and has described the product as a major source of company revenue. Exact current-year revenue, gross-to-net deductions, operating profit, and geographic revenue are not reported with the transparency of a public pharmaceutical company. [6,7]
Financial drivers
| Driver |
Effect on revenue |
| Growth in obesity diagnosis and treatment |
Expands patient pool |
| Oral administration |
Supports use where injectable therapy is unsuitable or unaffordable |
| Lower price than newer incretin therapies |
Improves self-pay and cash-pay positioning |
| GLP-1 and GIP/GLP-1 competition |
Reduces prescribing share and pricing power |
| Telehealth distribution |
Expands reach but increases customer-acquisition costs |
| Payer coverage |
Determines refill persistence and net price |
| Generic entry |
Creates the largest long-term revenue risk |
| Formulation and manufacturing complexity |
Can delay substitution after patent expiry |
The most favorable financial scenario is continued growth in lower-cost oral obesity therapy while GLP-1 products remain inaccessible because of price, shortages, contraindications, or patient preference. The weaker scenario is broad insurance coverage for semaglutide and tirzepatide combined with generic bupropion/naltrexone ER entry.
When does Contrave lose exclusivity?
FDA regulatory exclusivity expired years before the principal patent barriers. Contrave received three-year new clinical investigation exclusivity associated with approval of a combination containing previously known active ingredients. That period generally ran through September 2017. The product did not receive the five-year new chemical entity exclusivity normally associated with a novel active ingredient. [1,8]
Patent protection has extended beyond regulatory exclusivity through patents directed to the combination, dosing, formulation, and methods of treating obesity. The practical generic-entry date depends on the specific patents listed in the Orange Book, the certifications made by each ANDA applicant, litigation outcomes, settlements, and any applicable pediatric or patent-term adjustments.
Key exclusivity timeline
| Date |
Event |
| September 2014 |
FDA approves Contrave |
| September 2017 |
Three-year FDA clinical-investigation exclusivity generally expires |
| 2018 |
Orexigen enters bankruptcy proceedings |
| 2018-2019 |
Contrave assets move to Nalpropion/Currax ownership |
| 2020-2024 |
Patent litigation and ANDA challenges continue around extended-release combination claims |
| 2025 onward |
Increasing risk of generic competition as later-listed patent barriers mature |
The effective loss of exclusivity is therefore a staged process rather than a single date. Earlier composition or method patents may expire before later formulation patents. A generic product can also remain blocked after one patent expires if another listed patent is successfully enforced.
What patents protect Contrave?
Contrave’s patent estate has included patents covering the naltrexone/bupropion combination, sustained or extended release, dosage escalation, and methods of achieving weight loss.
Publicly identified patent families associated with Contrave and its development history include the following:
| Patent number or family |
General subject matter |
Commercial relevance |
| U.S. Patent No. 7,375,111 |
Combination treatment and obesity-related methods |
Earlier foundational protection |
| U.S. Patent No. 8,034,800 |
Combination therapy and dosing concepts |
Potential method-of-use barrier |
| U.S. Patent No. 8,865,688 |
Extended-release naltrexone/bupropion compositions |
Core formulation protection |
| U.S. Patent No. 9,101,622 |
Dosage and treatment regimens |
Later method-of-use protection |
| Later continuation families |
Formulation, dosing, and treatment claims |
Potentially extend litigation and launch complexity |
Patent numbers and expiration dates must be evaluated against the current FDA Orange Book record and the prosecution history of each continuation. Patent term adjustment, terminal disclaimers, reexamination, claim amendments, and post-grant proceedings can alter the practical scope of protection.
The strongest commercial barriers are usually the formulation and method-of-use patents rather than claims directed broadly to the two active ingredients. An ANDA applicant may be able to avoid some method claims through a label carve-out, but a formulation patent can present a more direct barrier if the proposed generic uses the same extended-release architecture.
What is the Orange Book status of Contrave?
Contrave has been listed in the FDA Orange Book with patents associated with its approved drug product. Orange Book listings provide the basis for ANDA applicants to submit Paragraph IV certifications asserting that listed patents are invalid, unenforceable, or not infringed.
The Orange Book does not guarantee that every listed patent will block generic launch. It identifies patents that the sponsor has submitted as relevant to the approved product. The applicant’s proposed labeling, dosage form, formulation, and manufacturing process determine which patents are exposed to challenge.
The principal Orange Book risks are:
- Paragraph IV litigation against formulation patents.
- Method-of-use litigation if the generic label retains the patented obesity indication.
- Delayed generic approval during the 30-month stay triggered by timely litigation.
- Launch at risk if the ANDA applicant prevails before final judgment.
- Settlement-based entry dates that may precede or follow nominal patent expiration.
Which companies have challenged Contrave patents?
Generic-drug companies have challenged Contrave’s patent estate through ANDA filings and Paragraph IV certifications. Public litigation has involved major generic manufacturers, including Actavis-related entities and other ANDA applicants.
The standard litigation pattern is:
- An ANDA applicant notifies the patent owner of a Paragraph IV certification.
- The sponsor files an infringement action within 45 days.
- FDA approval is generally stayed for up to 30 months, subject to court decisions and statutory exceptions.
- The case proceeds through claim construction, validity and infringement disputes, or settlement.
- The applicant may launch after a favorable judgment, settlement date, or patent expiration.
Settlement agreements may include a permitted-entry date, supply arrangements, royalty terms, authorized-generic provisions, or restrictions on the scope of the generic label. Many commercial terms remain confidential. Public docket records and FDA approval records are more reliable than promotional statements for determining whether a specific generic has an approved and launchable product.
What generic entry risks exist for Contrave?
Generic substitution presents a high long-term risk because both active ingredients are inexpensive and widely manufactured. The remaining barriers are technical and legal:
Formulation risk
Contrave uses extended-release tablets containing two active ingredients with different pharmacologic profiles. A generic applicant must reproduce dissolution, stability, content uniformity, bioequivalence, and manufacturing performance. The product is not equivalent to simply combining immediate-release bupropion and naltrexone tablets.
Regulatory risk
An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. The applicant also must address any Orange Book patents through Paragraph IV, Section viii, or certification that the patents have expired.
Label risk
A generic seeking to remove a patented method of use may use a section viii statement and carve out the protected indication. That approach may be difficult where obesity treatment is the central commercial use and the remaining label does not support meaningful sales.
Commercial risk
Generic entry could reduce the branded product’s price, payer preference, refill economics, and promotional return. Contrave could retain market share through brand loyalty, patient-support programs, telehealth access, and contracts with cash-pay channels, but those advantages would not prevent broad substitution in pharmacy benefit plans.
How strong is the Contrave patent estate?
The estate is moderate rather than foundational.
Its strengths are:
- Multiple patent families rather than one expiration date.
- Formulation claims that may be difficult to design around.
- Method-of-use claims linked to the approved obesity indication.
- A clinically established product with a defined reference formulation.
- Potential for litigation delay and negotiated generic-entry dates.
Its weaknesses are:
- The active ingredients are old and broadly available.
- FDA exclusivity has expired.
- The product’s commercial value is concentrated in a known combination.
- Formulation and method patents face validity and obviousness challenges.
- Generic manufacturers can pursue alternative formulations or label strategies.
- Newer obesity drugs reduce the economic value of prolonged patent protection.
The estate may delay generic substitution, but it is unlikely to support durable monopoly pricing comparable to a novel molecular entity.
What manufacturing and intellectual-property barriers affect the product?
Manufacturing risk is concentrated in the extended-release tablet. The manufacturer must control release kinetics for both ingredients while maintaining stability and dose uniformity. Scale-up, coating, granulation, particle-size control, dissolution testing, and impurity management can affect regulatory approval.
The commercial owner may also retain non-patent protection through:
- Manufacturing know-how.
- Supplier qualification.
- Stability data.
- Batch-release specifications.
- Packaging and distribution systems.
- Patient-titration programs.
- Brand and telehealth relationships.
These protections can delay or complicate competition but generally do not prevent generic substitution once an approved ANDA is available.
How does Contrave compare with GLP-1 obesity drugs?
Contrave occupies the lower-cost oral segment. Wegovy and Zepbound offer substantially greater average weight loss but have higher acquisition costs, injectable administration, broader demand, and payer-management challenges.
| Factor |
Contrave |
Wegovy/Zepbound |
| Administration |
Oral |
Injectable |
| Active mechanism |
Naltrexone/bupropion |
GLP-1 or GIP/GLP-1 |
| Average efficacy |
Moderate |
High to very high |
| Cost positioning |
Lower |
Higher |
| Opioid compatibility |
Contraindicated with chronic opioid use |
Generally not subject to the same opioid restriction |
| Supply concerns |
Lower manufacturing complexity than injectables |
Historically significant demand and supply pressure |
| Patent outlook |
Mature combination-product estate |
Extensive molecular, formulation and device estates |
| Main commercial channel |
Retail, telehealth, cash-pay |
Retail, specialty and payer-managed channels |
Contrave is most defensible where patients need oral treatment, cannot access or tolerate incretin therapy, or face high out-of-pocket costs.
What is the likely generic launch scenario?
The most likely launch pattern is staggered entry rather than immediate multisource competition. One or more manufacturers may launch after resolving patent litigation, followed by additional ANDA approvals. Initial generic pricing may remain above marginal manufacturing cost if only one or two suppliers enter.
A branded-revenue decline would likely occur in stages:
- First, reduced new prescriptions as physicians anticipate generic substitution.
- Second, payer substitution after the first approved generic.
- Third, sharper price erosion as multiple manufacturers enter.
- Fourth, stabilization around a lower-volume, lower-price maintenance market.
Currax can slow erosion through authorized-generic arrangements, contracting, direct-to-consumer channels, and indication-specific marketing. Those measures typically preserve some revenue but do not replicate pre-entry branded economics.
Key Takeaways
- Contrave is the principal commercial product combining bupropion hydrochloride and naltrexone hydrochloride for obesity.
- The active ingredients are generic; the value lies in the extended-release combination, clinical data, brand, and distribution.
- FDA regulatory exclusivity expired in 2017, while formulation and method-of-use patents created later barriers.
- Currax’s public disclosures indicate annual Contrave sales above $100 million, but detailed audited financial statements are not publicly available.
- GLP-1 and GIP/GLP-1 medicines represent the largest competitive threat because of superior average weight-loss efficacy.
- Generic risk is substantial because the ingredients are inexpensive and widely available.
- The most important patent issues concern extended-release formulation, dosing, method of use, and the timing of Paragraph IV litigation.
- The likely post-exclusivity market is a lower-price oral obesity segment with continuing demand from patients who cannot access, tolerate, or afford injectable incretin therapies.
FAQs About Bupropion/Naltrexone Market and Patent Risk
Is bupropion/naltrexone the same as Contrave?
Contrave is the branded extended-release fixed-dose combination of naltrexone hydrochloride and bupropion hydrochloride. Separate immediate-release or extended-release products containing either ingredient are not automatically therapeutically equivalent to Contrave.
Can patients take generic bupropion and naltrexone instead of Contrave?
Patients should not assume that separate generic products reproduce Contrave’s dose escalation, release profile, bioequivalence, or approved labeling. Substitution depends on the prescriber, pharmacist, formulation, and applicable regulatory requirements.
Does Contrave have orphan-drug or biologic exclusivity?
No. Contrave is a small-molecule combination product and does not have biologic or biosimilar exclusivity. Its protection comes from FDA regulatory exclusivity, patents, formulation know-how, and commercial execution.
What is the largest commercial threat to Contrave?
The largest threat is the combination of high-efficacy incretin therapies and eventual generic extended-release naltrexone/bupropion competition. GLP-1 and GIP/GLP-1 products pressure prescribing share, while generics pressure price.
Can Contrave retain value after generic entry?
Yes, but at lower margins. Brand value may persist through patient familiarity, telehealth distribution, cash-pay pricing, patient-support programs, and use in patients who prefer oral treatment or cannot use incretin therapies.
References
- U.S. Food and Drug Administration. (2024). Contrave prescribing information. FDA.
- Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K., & Cowley, M. A. (2010). Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. Journal of Clinical Endocrinology & Metabolism, 95(11), 4898-4906.
- Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384, 989-1002.
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387, 205-216.
- Orexigen Therapeutics, Inc. (2018). Form 10-K and bankruptcy-related disclosures.
- Currax Pharmaceuticals LLC. (2023). Corporate and Contrave commercial disclosures.
- Nalpropion Pharmaceuticals LLC. (2018). Acquisition and commercialization materials for Contrave.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
